Clinical Trial to Preliminarily Assess the Safety and Feasibility of SAT-014, a Software for Alleviating Symptoms of Trauma and Stress-related Disorders
An Open-label, Randomized, Controlled, Exploratory Clinical Trial to Preliminarily Assess the Safety and Feasibility of SAT-014, a Software for Alleviating Symptoms of Trauma and Stress-related Disorders
1 other identifier
interventional
20
1 country
1
Brief Summary
Failure to adapt to stress leads to functional impairments in various areas, including social, occupational, educational, and other significant domains, necessitating therapeutic intervention. Interventions through mobile app in the form of software can provide a new alternative for alleviating symptoms caused by psychological trauma by increasing accessibility to early intervention for trauma patients. This study aims to preliminarily assess the safety and feasibility of a psychological traum intervention by developing SAT-014 to help patients with trauma and stress-related disorder continue effective treatment in a stable environment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Jan 2024
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 3, 2024
CompletedFirst Submitted
Initial submission to the registry
May 27, 2024
CompletedFirst Posted
Study publicly available on registry
June 3, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 28, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2024
CompletedDecember 20, 2024
August 1, 2024
6 months
May 27, 2024
December 17, 2024
Conditions
Outcome Measures
Primary Outcomes (7)
Change in IES-R (Impact Event Scale-Revised) score
The Korean version of the Impact Event Scale-Revised (IES-R) consists of 22 items each rated on a 5-point scale ranging from 0 to 4. The total score ranges from 0 to 88, with higher scores indicating a greater risk of post-traumatic stress disorder and a worse outcome.
Baseline, 3weeks, 6weeks, 10weeks
Change in PCL-5 (PTSD Checklist-5) score
The PTSD Checklist for DSM-5 (PCL-5) consists of 20 items, each rated on a scale from 0 to 4. The total score ranges from 0 to 80, with higher scores indicating greater distress due to symptoms related to past stressful experiences and a worse outcome.
Baseline, 3weeks, 6weeks, 10weeks
Change in GAD-7 (Generalized Anxiety Disorder 7 item scale) score
The Generalized Anxiety Disorder 7-item scale (GAD-7) consists of 7 items, each rated on a scale from 0 to 3. The total score ranges from 0 to 21, with higher scores indicating more severe anxiety symptoms and a worse outcome.
Baseline, 3weeks, 6weeks, 10weeks
Change in BAI (Beck Anxiety Inventory) score
The Beck Anxiety Inventory (BAI) consists of 21 items, each rated on a scale from 0 to 3. The total score ranges from 0 to 63, with higher scores indicating more severe anxiety symptoms and a worse outcome.
Baseline, 3weeks, 6weeks, 10weeks
Change in PHQ-9 (Patient Health Questionnaire-9; depression screening tool) score
The Patient Health Questionnaire-9 (PHQ-9) consists of 9 items, each rated on a scale of 0 to 3. The total score ranges from 0 to 27, with higher scores indicating more severe symptoms and a worse outcome.
Baseline, 3weeks, 6weeks, 10weeks
Change in QIDS-SR (Quick Inventory of Depressive Symptomatology-Self Report) score
The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) consist of 16 items, each rated on a scale of 0 to 3. It evaluates responses to 16 items based on criteria for nine depressive symptoms. The total score ranges from 0 to 27, with higher scores indicating more severe symptoms and a worse outcome.
Baseline, 3weeks, 6weeks, 10weeks
Change in CGI (Clinical Global Impression) score
The CGI consists of two items: (a) the clinician's overall impression of the patient's severity of illness and (b) global improvement over time. The severity of illness is rated on a scale from 1 to 7, with a higher score indicating more severe illness and a worse outcome. Global improvement is also rated on a scale from 1 to 7, with a higher score indicating a worse outcome.
Baseline, 3weeks, 6weeks, 10weeks
Study Arms (2)
SAT-014
EXPERIMENTALMaintain previous treatment
OTHERInterventions
SAT-014(Software as Medical Device) + maintain previous treatment
Eligibility Criteria
You may qualify if:
- Adults (19 years and older)
- Have experienced clinically significant psychological trauma within the 6 months prior to screening visit
- Met the diagnostic criteria for Post-Traumatic Stress Disorder (PTSD) or Adjustment Disorder (AD) category as evaluated by MINI (Mini-International Neuropsychiatric Interview)
- Score between 17 and 38 points on the IES-R (Impact of Event Scale-Revised)
- Score of 4 or less on CGI (Clinical Global Impression)
- Capable of complying the activity instructions provided the app
You may not qualify if:
- Have been diagnosed with schizophrenia, bipolar disorder, and psychotic disorder
- Have been diagnosed with neurodevelopmental disorder, neurocognitive disorder, or organic mental disorder
- Severe depression (PHQ-9 score of 20 or greater)
- Comorbid with severe personality disorder
- Diagnosed with substance use disorder excluding nicotine and caffeine and with severe alcohol use disorder
- Have made a suicide attempt within 3 months and are judged to be at high risk for suicide by a psychiatrist
- Pregnant or lactating
- Currently participating in another clinical trial or have participated in another trial within 90 days from screening
- Others deemed unsuitable for participation in this clinical trial at the discretion of the investigator due to ethical concerns or potential impact on the trial outcome
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Samsung Medical Center
Seoul, South Korea
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 27, 2024
First Posted
June 3, 2024
Study Start
January 3, 2024
Primary Completion
June 28, 2024
Study Completion
August 30, 2024
Last Updated
December 20, 2024
Record last verified: 2024-08